Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) open the trading on Wednesday, with great promise as it jumped 2.50% to $6.57, before settling in for the price of $6.41 at the close. Taking a more long-term approach, AMLX posted a 52-week range of $1.62-$7.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -78.71%. Meanwhile, its Annual Earning per share during the time was -78.71%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 59.46%. This publicly-traded company’s shares outstanding now amounts to $89.08 million, simultaneously with a float of $65.31 million. The organization now has a market capitalization sitting at $585.65 million. At the time of writing, stock’s 50-day Moving Average stood at $5.27, while the 200-day Moving Average is $4.32.
Amylyx Pharmaceuticals Inc (AMLX) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Amylyx Pharmaceuticals Inc’s current insider ownership accounts for 26.74%, in contrast to 80.07% institutional ownership. According to the most recent insider trade that took place on Mar 31 ’25, this organization’s Chief Financial Officer sold 10,896 shares at the rate of 3.47, making the entire transaction reach 37,806 in total value, affecting insider ownership by 290,988. Preceding that transaction, on Mar 31 ’25, Company’s Chief Medical Officer sold 12,425 for 3.47, making the whole transaction’s value amount to 43,082. This particular insider is now the holder of 194,375 in total.
Amylyx Pharmaceuticals Inc (AMLX) Earnings and Revenue Records
Amylyx Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 59.46% and is forecasted to reach -1.45 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 29.78% through the next 5 years, which can be compared against the -78.71% growth it accomplished over the previous five years trading on the market.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Trading Performance Indicators
Let’s observe the current performance indicators for Amylyx Pharmaceuticals Inc (AMLX). It’s Quick Ratio in the last reported quarter now stands at 12.05.
In the same vein, AMLX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.10, a figure that is expected to reach -0.46 in the next quarter, and analysts are predicting that it will be -1.45 at the market close of one year from today.
Technical Analysis of Amylyx Pharmaceuticals Inc (AMLX)
[Amylyx Pharmaceuticals Inc, AMLX] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 85.20% While, its Average True Range was 0.46.
Raw Stochastic average of Amylyx Pharmaceuticals Inc (AMLX) in the period of the previous 100 days is set at 93.30%, which indicates a major rise in contrast to 86.13% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 106.63% that was higher than 86.48% volatility it exhibited in the past 100-days period.
